Sanofi and Translate Bio Collaborate Over COVID-19 Vaccine Candidate
Sanofi announced that it will partner with Translate Bio to develop a novel mRNA vaccine candidate for COVID-19.
Under the partnership, Translate Bio will use its mRNA platform to discover, design, and manufacture vaccine candidates. Sanofi will provide support from its research networks to advance the vaccine candidates for further development.
Sanofi has also partnered with HHS to advance a recombinant, protein-based vaccine candidate.